- Home
- RXO vs VRDN Comparison
RXO vs VRDN Comparison
Compare RXO & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RXO | VRDN |
|---|---|---|
| Founded | 2022 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.7B |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RXO | VRDN |
|---|---|---|
| Price | $13.91 | $27.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $16.38 | ★ $40.92 |
| AVG Volume (30 Days) | ★ 1.7M | 1.0M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,742,000,000.00 | $5,706,000.00 |
| Revenue This Year | $0.78 | $27.65 |
| Revenue Next Year | $6.58 | $253.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.20 | N/A |
| 52 Week Low | $10.43 | $9.90 |
| 52 Week High | $19.65 | $34.29 |
Technical Indicators
Market Signals| Indicator | RXO | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 44.69 |
| Support Level | $12.01 | $26.31 |
| Resistance Level | $16.62 | $33.71 |
| Average True Range (ATR) | 0.81 | 1.06 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 68.75 | 43.38 |
Price Performance
Historical ComparisonAbout RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).